Novasep Invests €10M to Reinforce its Bioconjugation Services

Novasep will build a fully integrated Antibody Drug Conjugate (ADC) facility at its Le Mans site in France. The new facility will enable Novasep to complement its current ADC offering with full bio-conjugation services to meet increasing market demand.

The facility is planned to be commissioned in Q2 2016. It will provide contract manufacturing in batch sizes from a few milligrams to 600 g to ADC drug developers during clinical trial and commercial development phases.

“Combining chemistry and biology is not a given. Novasep is one of the few CMOs able to produce both commercial scale ADCs payloads and monoclonal antibodies,” said Thierry Van Nieuwenhove, president of Novasep’s Synthesis BU. “Customers are now searching for a simplified supply chain to produce their ADC and other bio-conjugate drug substances. By integrating our R&D, analytical and manufacturing services within a single unit, we can give customers flexibility, assurance of supply and continuity in supply chains.”

Novasep’s €10 million investment in clinical and commercial scale ADC conjugation is a natural extension to its existing CMO offering and leverages its unique purification technologies. Novasep’s new ADC facility, whose design is now complete, will be capable of producing ADCs in full compliance with the highest standards in quality, health, environmental and industrial safety.

“This move is part of our “Back to basics” strategy, forging Novasep’s re-focus on growing core businesses,” said Dr Michel Spagnol, chairman and CEO of Novasep. “We are proud to see our Le Mans site continuing its growth in one of the pharmaceutical industry’s most exciting development areas.”